Matthias Gromeier, Durham, NC (US); John H. Sampson, Durham, NC (US); Darell D. Bigner, Mebane, NC (US); Annick Desjardins, Durham, NC (US); and Henry S. Friedman, Durham, NC (US)
Assigned to Duke University, Durham, NC (US)
Filed by Duke University, Durham, NC (US)
Filed on Jul. 5, 2022, as Appl. No. 17/857,534.
Application 16/505,771 is a division of application No. 15/428,510, filed on Feb. 9, 2017, granted, now 10,398,743, issued on Sep. 3, 2019.
Application 15/428,510 is a division of application No. 14/646,233, abandoned, previously published as PCT/US2013/071246, filed on Nov. 21, 2013.
Application 17/857,534 is a continuation of application No. 17/016,699, filed on Sep. 10, 2020, granted, now 11,406,677.
Application 17/016,699 is a continuation of application No. 16/505,771, filed on Jul. 9, 2019, granted, now 10,799,543, issued on Oct. 13, 2020.
Claims priority of provisional application 61/729,021, filed on Nov. 21, 2012.
Prior Publication US 2022/0339223 A1, Oct. 27, 2022
1. A method for treating a human patient having a melanoma tumor, the method comprising: administering by directly injecting into the melanoma tumor a chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in the poliovirus's 5′ untranslated region between the poliovirus's cloverleaf and the poliovirus's open reading frame.